Alpha 1-adrenergic blockade reduces exercise-induced regional myocardial ischemia in dogs.

B D Guth, T Miura, E Thaulow, G Heusch, J Ross
Author Information
  1. B D Guth: Department of Medicine, University of California, San Diego, La Jolla.

Abstract

The effect of selective alpha 1-adrenoceptor blockade on regional myocardial blood flow and contractile function during exercise-induced myocardial ischemia was determined in nine dogs having chronic single vessel coronary stenosis (ameroid constrictor). Treadmill exercise performed after beta-adrenoceptor blockade (1.0 mg/kg i.v. propranolol), to block potential prejunctional effects recently recognized with alpha-blockade, elicited severe regional myocardial ischemia with a steady-state reduction of regional systolic wall thickening of the post-stenotic myocardium from a resting value of 21.8% to 7.0%. Blood flow to the ischemic subendocardium was reduced from 0.76 to 0.36 ml/min/g (microspheres). Prazosin (80 micrograms/kg i.v.) was administered during continued running, and angiotensin II was simultaneously infused to prevent the decrease in systemic arterial pressure caused by prazosin. During the subsequent steady state, with arterial pressure matched to the pre-prazosin level, regional subendocardial blood flow improved to 0.60 ml/min/g and systolic wall thickening in the post-stenotic region increased modestly to 10.2%. No changes in blood flow to the outer portion of the post-stenotic region or to the remote control region were seen, and prazosin caused no effect on regional function in the control area, indicating effective blockade of prejunctional effects of prazosin (demonstrated in pilot studies). The finding that blockade of alpha 1-adrenoceptors resulted in improved ischemic zone subendocardial blood flow and contractile function are consistent with alpha 1-adrenoceptor-mediated reduction of blood flow to the ischemic subendocardium during exercise-induced ischemia in dogs with beta-blockade.

References

  1. Am J Physiol. 1982 Nov;243(5):H698-707 [PMID: 7137363]
  2. Naunyn Schmiedebergs Arch Pharmacol. 1986 Oct;334(2):156-65 [PMID: 3024031]
  3. Circ Res. 1986 Jan;58(1):68-82 [PMID: 3002658]
  4. Circ Res. 1979 Nov;45(5):654-60 [PMID: 39683]
  5. Circ Res. 1986 Aug;59(2):133-42 [PMID: 2874899]
  6. Am J Physiol. 1988 May;254(5 Pt 2):H984-92 [PMID: 2896466]
  7. Can J Cardiol. 1986 Jul;Suppl A:9A-18A [PMID: 3756604]
  8. J Cardiovasc Pharmacol. 1988 Jan;11(1):61-7 [PMID: 2450258]
  9. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):961-8 [PMID: 6209507]
  10. Pflugers Arch. 1977 Dec 12;372(2):187-94 [PMID: 202920]
  11. Circulation. 1987 Feb;75(2):482-90 [PMID: 3802450]
  12. Circulation. 1987 Mar;75(3):661-9 [PMID: 3815774]
  13. Am J Physiol. 1985 Mar;248(3 Pt 2):H403-11 [PMID: 3156514]
  14. Am J Cardiol. 1986 Feb 1;57(4):195-8 [PMID: 2868648]
  15. Am J Physiol. 1987 Sep;253(3 Pt 2):H582-90 [PMID: 2888319]
  16. Am J Physiol. 1986 Apr;250(4 Pt 2):H645-53 [PMID: 2870645]
  17. Rev Physiol Biochem Pharmacol. 1990;116:77-165 [PMID: 2293307]
  18. Circ Res. 1988 Feb;62(2):216-25 [PMID: 2827908]
  19. Am J Physiol. 1985 Sep;249(3 Pt 2):H638-47 [PMID: 4037109]
  20. Eur J Pharmacol. 1985 Sep 24;115(2-3):147-53 [PMID: 2866101]
  21. Circulation. 1985 Feb;71(2):370-7 [PMID: 3965177]
  22. Am J Physiol. 1985 Dec;249(6 Pt 2):H1070-7 [PMID: 2866717]
  23. Prog Cardiovasc Dis. 1989 May-Jun;31(6):455-66 [PMID: 2652192]
  24. Circulation. 1991 Oct;84(4):1715-24 [PMID: 1680577]
  25. Am J Physiol. 1982 May;242(5):H805-9 [PMID: 7081452]
  26. Am J Physiol. 1984 Jul;247(1 Pt 2):H52-60 [PMID: 6146266]
  27. Physiol Rev. 1983 Jan;63(1):1-205 [PMID: 6296890]
  28. Eur J Pharmacol. 1982 Aug 27;82(3-4):199-202 [PMID: 6290236]
  29. Circ Res. 1990 Jun;66(6):1703-12 [PMID: 1971537]
  30. Circulation. 1992 Jan;85(1):313-22 [PMID: 1728463]
  31. Am J Physiol. 1986 Jun;250(6 Pt 2):H1117-26 [PMID: 3013025]
  32. J Auton Nerv Syst. 1985 Aug;13(4):311-26 [PMID: 4031366]
  33. Circ Res. 1983 Jul;53(1):8-15 [PMID: 6861299]
  34. Circ Res. 1989 Dec;65(6):1688-97 [PMID: 2555079]
  35. Circ Res. 1988 Mar;62(3):436-42 [PMID: 2893669]

Grants

  1. 1F05 TWO3753-01 BI-5 (12)/FIC NIH HHS
  2. HL-17682/NHLBI NIH HHS

MeSH Term

Adrenergic alpha-Antagonists
Animals
Coronary Circulation
Dogs
Hemodynamics
Myocardial Contraction
Myocardial Ischemia
Physical Exertion
Prazosin

Chemicals

Adrenergic alpha-Antagonists
Prazosin

Word Cloud

Created with Highcharts 10.0.0regionalflowblockadebloodmyocardialischemia0alphafunctionexercise-induceddogspost-stenoticischemicprazosinregioneffectcontractileivprejunctionaleffectsreductionsystolicwallthickeningsubendocardiumml/min/garterialpressurecausedsubendocardialimprovedcontrolselective1-adrenoceptordeterminedninechronicsinglevesselcoronarystenosisameroidconstrictorTreadmillexerciseperformedbeta-adrenoceptor1mg/kgpropranololblockpotentialrecentlyrecognizedalpha-blockadeelicitedseveresteady-statemyocardiumrestingvalue218%70%Bloodreduced7636microspheresPrazosin80micrograms/kgadministeredcontinuedrunningangiotensinIIsimultaneouslyinfusedpreventdecreasesystemicsubsequentsteadystatematchedpre-prazosinlevel60increasedmodestly102%changesouterportionremoteseenareaindicatingeffectivedemonstratedpilotstudiesfinding1-adrenoceptorsresultedzoneconsistent1-adrenoceptor-mediatedbeta-blockadeAlpha1-adrenergicreduces

Similar Articles

Cited By